PPAR-γ agonism for cardiovascular and renal protection. - Wikidata - wikimedia - TriplyDB

PPAR-γ agonism for cardiovascular and renal protection.

PPAR-γ agonism for cardiovascular and renal protection.

http://www.wikidata.org/entity/Q37788729

about

Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes.Inhibition of TGF-β by a novel PPAR-γ agonist, chrysin, salvages β-receptor stimulated myocardial injury in rats through MAPKs-dependent mechanism.Effects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouse PPARγ signaling and metabolism: the good, the bad and the future.The effect of pioglitazone on antioxidant levels and renal histopathology in streptozotocin-induced diabetic rats The Preventive Role of Pioglitazone in Glycerol-Induced Acute Kidney Injury in Rats during Two Different Treatment Periods.

P2860

Q26851905-F80048A6-D06C-4B24-83D1-0C996DC958F1 Q35174597-1052017B-59E6-4F62-B38C-A951DE94124D Q35177115-7592ED72-1F0B-437D-BE8A-BB256902204F Q35498269-4273621B-EF4D-4134-80AA-E606E7F84A83 Q37407887-63D959C0-1A07-4307-B566-409BC7CE0C39 Q41095013-557E349D-0DC6-41DD-877B-3FC1435BB775 Q54985660-70871A50-B226-4609-8802-3D47AEE87B7D

P2860

PPAR-γ agonism for cardiovascular and renal protection.

http://www.wikidata.org/entity/Q37788729

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 September 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PPAR-γ agonism for cardiovascular and renal protection.

@en

PPAR-γ agonism for cardiovascular and renal protection.

@nl

type

label

PPAR-γ agonism for cardiovascular and renal protection.

@en

PPAR-γ agonism for cardiovascular and renal protection.

@nl

prefLabel

PPAR-γ agonism for cardiovascular and renal protection.

@en

PPAR-γ agonism for cardiovascular and renal protection.

@nl

P1433

Q37788729-84182286-F879-47CE-9388-48E6D0369230

P1476

Q37788729-B7D56280-AE33-45FA-AC10-5FF1BE88A05F

P2093

Q37788729-61D2F862-0617-4F6C-9E68-7C96E4FE1027

Q37788729-9507B73B-A911-4426-BAA0-CF991C8F9801

Q37788729-BD837B02-57B8-4D44-BC5E-AE5037688053

P2860

Q37788729-0252C4A5-384C-41C0-86E0-2CDCAA65364E

Q37788729-05B1D152-DB64-4A0A-AF5D-8421D85F99F2

Q37788729-088D3A03-5197-4225-B39C-5D1B39C23C3C

Q37788729-0CC82B67-C876-41D3-B9C7-4B6E59BF2A5C

Q37788729-0D26AA01-0DA2-4A40-8B58-B3046AA9EB25

Q37788729-182AB62F-8EC2-45CD-978D-BBF582EA6CFB

Q37788729-1B6BE5E7-9C5E-4DB6-AC6C-22172BC373D8

Q37788729-1C893C5D-BB34-40A4-85A7-8609B7950C0A

Q37788729-1DFB4DD0-4277-42FF-BA70-61054E12DBC1

Q37788729-2A422A23-A471-4540-A287-AE1D100D7169

P304

Q37788729-F5148EA1-B140-4168-89C2-13F2299EB61C

P31

Q37788729-3C178D11-E33B-4ECC-9CAA-C764880B7F51

P356

Q37788729-3784E459-E498-4A98-B1C5-C0E568AF30D2

P433

Q37788729-8252C347-7859-4F68-B634-53341DAE1D28

P478

Q37788729-C19F932D-3ABB-4F8C-B78E-EFAF66266431

P577

Q37788729-35554409-4A2B-47E9-A1EE-EC0F338176F6

P5875

Q37788729-625FE491-0418-4273-A6C6-24A6F4605F49

P698

Q37788729-59C5A3D5-8A24-401F-A4B5-58B7B8C03AEE

P356

J.1755-5922.2010.00222.X

P1433

Cardiovascular Therapeutics

P1476

PPAR-γ agonism for cardiovascular and renal protection.

@en

P2093

Anastasios N Lasaridis

http://www.w3.org/2001/XMLSchema#string

Panagiotis I Georgianos

http://www.w3.org/2001/XMLSchema#string

Pantelis A Sarafidis

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.

Insulin resistance and its treatment by thiazolidinediones.

Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches.

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis.

P304

377-384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1755-5922.2010.00222.X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46271957

http://www.w3.org/2001/XMLSchema#string

P698

20840193

http://www.w3.org/2001/XMLSchema#string